[1] |
Muro Y, Sugiura K, Akiyama M. Cutaneous manifestations in dermatomyositis: key clinical and serological features⁃a comprehensive review[J]. Clin Rev Allergy Immunol, 2016, 51(3): 293⁃302. DOI: 10.1007/s12016⁃015⁃8496⁃5.
|
[2] |
Quinter SD, Chiu YE, Lyon VB, et al. Inverse Gottron′s papules: an unusual cutaneous manifestation of juvenile dermatomyositis[J]. Pediatr Dermatol, 2012, 29(5): 641⁃644. DOI: 10.1111/j. 1525⁃1470.2011.01585.x.
|
[3] |
del PJ, Almagro M, Martínez W, et al. Dermatomyositis and mucinosis[J]. Int J Dermatol, 2001, 40(2): 120⁃124.
|
[4] |
Sasaki Y, Okuyama R, Tsunoda T, et al. Keratotic palmar papules in a dermatomyositis patient preceding the development of interstitial pneumonia[J]. Dermatology, 2007, 215(2): 169⁃170. DOI: 10.1159/000104272.
|
[5] |
Fujimoto N, Honda S, Wakabayashi M, et al. Anti⁃MDA⁃5 anti⁃body positive bullous dermatomyositis with palmar papules comp⁃licating rapidly progressive interstitial lung disease[J]. Mod Rheumatol, 2016, 26(4): 614⁃616. DOI: 10.3109/14397595.2014. 908811.
|
[6] |
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7): 344⁃347. DOI: 10.1056/NEJM197502132920706.
|
[7] |
Hoogendijk JE, Amato AA, Lecky BR, et a1. 119th ENMC international workshop: trial design in adult idiopathic inflam⁃matory myopathies, with the exception of inclusion bodymyositis, 10⁃12 October 2003, Naarden, The Netherlands[J]. Neuromuscul Disord, 2004, 14 (5): 337⁃345. DOI: 10.1016/j.nmd.2004.02.006.
|
[8] |
Iaccarino L, Ghirardello A, Bettio S,et a1.The clinical features, diagnosis and classification of dermatomyositis[J]. J Autoimmun, 2014, 48⁃49: 122⁃127. DOI: 10.1016/j.jaut.2013.11.005.
|
[9] |
杨莹, 曹元华, 闫桢桢, 等. 皮肌炎的皮肤表现及其意义[J]. 中华皮肤科杂志, 2013, 46(6): 450⁃453. DOI: 10.3760/cma.j.issn. 0412⁃4030.2013.06.031.
|
[10] |
Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM⁃140): a retrospective study[J]. J Am Acad Dermatol, 2011, 65(1): 25⁃34. DOI: 10.1016/j.jaad.2010.09.016.
|
[11] |
Hoshino K, Muro Y, Sugiura K, et al. Anti⁃MDA5 and anti⁃TIF1⁃gamma antibodies have clinical significance for patients with dermatomyositis[J]. Rheumatology (Oxford), 2010, 49(9): 1726⁃1733. DOI: 10.1093/rheumatology/keq153.
|
[12] |
Chaisson NF, Paik J, Orbai AM, et al. A novel dermato⁃pulmonary syndrome associated with MDA⁃5 antibodies: report of 2 cases and review of the literature[J]. Medicine (Baltimore), 2012, 91(4): 220⁃228. DOI: 10.1097/MD.0b013e3182606f0b.
|
[13] |
Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti⁃melanoma differentiation⁃associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM[J]. Rheumatology (Oxford), 2012, 51(7): 1278⁃1284. DOI: 10.1093/rheumatology/ker518.
|
[14] |
Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis[J]. J Rheumatol, 2005, 32(9): 1719⁃1726.
|